Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
68,025.70 +957.63 (+1.43%) CMC Crypto 200
1,378.75 +48.15 (+3.62%)
AstraZeneca PLC (AZNCF)
| Previous close | 157.49 |
| Open | 157.49 |
| Bid | 154.33 x 45900 |
| Ask | 164.60 x 40000 |
| Day's range | 157.49 - 157.49 |
| 52-week range | 118.16 - 162.00 |
| Volume | |
| Avg. volume | 2,261 |
| Market cap | 247.222B |
| Beta (5Y monthly) | 0.15 |
| PE ratio (TTM) | 38.80 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.97 (1.86%) |
| Ex-dividend date | 08 Aug 2024 |
| 1y target est | N/A |
- Business Wire
AstraZeneca’s H1 and Q2 2024 Financial Results
CAMBRIDGE, United Kingdom, July 25, 2024--H1/Q2 2024 Earnings Release (25 July 2024)
- CNW Group
Voydeya approved in Canada as add-on therapy to ravulizumab or eculizumab for adults with the rare disease PNH who have residual hemolytic anemia due to extravascular hemolysis
Voydeya (danicopan tablets) has been approved in Canada as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have residual hemolytic anemia due to extravascular hemolysis (EVH).1 Voydeya is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris (ravulizumab) or Soliris (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically sign
- Business Wire
IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
WILMINGTON, Del., June 25, 2024--Positive high-level results from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (EFS) and the key secondary endpoint of overall survival (OS) versus neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer (MIBC). Patients were treated with IMFINZI in combination wit
